Skip to main content

Table 2 Treatment-related toxicity

From: GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Adverse events N° of patients (%) grade according NCI-CTC vers. 4.03
G1 G2 G3 G4
Hypertension 1 (6 %) 1 (6 %)
Thromboembolic event 1 (6 %) 1 (6 %)
Diarrhea 2 (13 %) 1 (6 %)
Neutropenia 1 (6 %)
Hand Foot Syndrome 1 (6 %) 1 (6 %)
Epistaxis 1 (6 %)
Fatigue 2 (13 %)
  1. NCI-CTC, National Cancer InstituteCommon Toxicity Criteria